Target intelligence / Profile preview

Escherichia coli K99 antigen (K99)

Target
K99
Molecular classification
Bacterial adhesin, Fimbrial protein, Surface antigen
01

Overview

The Escherichia coli K99 antigen, also known as F5 fimbriae, is a filamentous surface protein expressed by enterotoxigenic E. coli (ETEC) that serves as a critical virulence factor in neonatal livestock [1, 4]. It functions as an adhesin, mediating the attachment of the bacteria to specific glycolipid receptors, such as N-glycolyl-GM3, on the intestinal epithelial cells of calves, lambs, and piglets [17]. This attachment is the essential first step for bacterial colonization of the small intestine, which is followed by the release of enterotoxins that cause severe secretory diarrhea, dehydration, and high mortality [15, 16]. Because of its pivotal role in infection, the K99 antigen is a major target for veterinary vaccines and passive immunization products [6, 10]. Maternal vaccines are used to stimulate anti-K99 antibodies in the dam's colostrum, which, when ingested by the neonate, provide passive protection by blocking bacterial docking and preventing disease [7, 11]. Additionally, therapeutic monoclonal antibodies targeting the K99 antigen can be administered directly to newborns to provide immediate, short-term immunity [3, 12]. The efficacy of these interventions is often monitored by measuring anti-K99 antibody titers in the colostrum or the serum of the offspring [11]. Understanding the molecular interaction between K99 and its host receptors remains vital for developing next-generation multivalent vaccines against neonatal colibacillosis [10, 13].

Other names
F5 fimbriaeK99 fimbriaeK99 pilusFanCK99 adhesin
02

Mechanism of action

Neutralization of bacterial adhesion by binding to the K99 fimbriae, thereby preventing the attachment of enterotoxigenic Escherichia coli to the intestinal epithelium and subsequent colonization.

03

Biological functions

Bacterial adhesionIntestinal colonizationPathogenesis
04

Disease associations

Neonatal diarrheaColibacillosisEnterotoxigenic Escherichia coli infection
05

Safety considerations

Injection site reactions in vaccinated damsInadequate colostrum intake leading to failure of passive transferPotential for emergence of non-K99 ETEC strains
06

Interacting drugs

ScourGuard 4KC

5 more in the full profile.

07

Biomarkers

K99-positive E. coli detection in fecal samplesAnti-K99 antibody titers in maternal serum or colostrumAnti-K99 antibody titers in neonatal serum

Beyond the preview

Go deeper on Escherichia coli K99 antigen (K99).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Escherichia coli K99 antigen (K99).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call